NRG Therapeutics Awarded Grant Funding from Target ALS to Support the Development of mPTP Inhibitors as Novel Treatments for ALS/MND
active portfolio companies
Investors and Venture Partners spanning Australia, New Zealand, United States and the United Kingdom